Industrial hemp contains, by weight, far less CBD than CBD-rich cultivars such as Harlequin or Sour Tsunami. This means that producing a single 10 mL dose of CBD would require the cultivation and extraction of far more hemp than it would from whole-plant marijuana; thus raising the risk of exposing users to more contaminants. Hemp is classified as a “bioaccumulator,” or a plant that naturally absorbs toxicants from the soil.
Fig. 5. Typical architecture of categories of cultivated Cannabis sativa. Top left: narcotic plants are generally low, highly branched, and grown well-spaced. Top right: plants grown for oilseed were traditionally well-spaced, and the plants developed medium height and strong branching. Bottom left: fiber cultivars are grown at high density, and are unbranched and very tall. Bottom center: “dual purpose” plants are grown at moderate density, tend to be slightly branched and of medium to tall height. Bottom right: some recent oilseed cultivars are grown at moderate density and are short and relatively unbranched. Degree of branching and height are determined both by the density of the plants and their genetic background.
Essential (volatile) oil in hemp is quite different from hempseed oil. Examples of commercial essential oil product products are shown in Fig. 42. The essential oil is a mixture of volatile compounds, including monoterpenes, sesquiterpenes, and other terpenoid-like compounds that are manufactured in the same epidermal glands in which the resin of Cannabis is synthesized (Meier and Mediavilla 1998). Yields are very small—about 10 L/ha (Mediavilla and Steinemann 1997), so essential oil of C. sativa is expensive, and today is simply a novelty. Essential oil of different strains varies considerably in odor, and this may have economic importance in imparting a scent to cosmetics, shampoos, soaps, creams, oils, perfumes, and foodstuffs. Switzerland has been a center for the production of essential oil for the commercial market. Narcotic strains tend to be more attractive in odor than fiber strains, and because they produce much higher numbers of flowers than fiber strains, and the (female) floral parts provide most of the essential oil, narcotic strains are naturally adapted to essential oil production. Switzerland has permitted strains with higher THC content to be grown than is allowed in other parts of the world, giving the country an advantage with respect to the essential oil market. However, essential oil in the marketplace has often been produced from low-THC Cannabis, and the THC content of essential oil obtained by steam distillation can be quite low, producing a product satisfying the needs for very low THC levels in food and other commercial goods. The composition of extracted essential oil is quite different from the volatiles released around the fresh plant (particularly limonene and alpha-pinene), so that a pleasant odor of the living plant is not necessarily indicative of a pleasant-smelling essential oil. Essential oil has been produced in Canada by Gen-X Research Inc., Regina. The world market for hemp essential oil is very limited at present, and probably also has limited growth potential.
“We have intellectual property that we’ve developed around how to manage hemp, and that we thought was prudent, because I think hemp is going to happen in the U.S. and when it does, I know that’s not the time to start,” said Canopy Chief Executive Bruce Linton in November’s earnings conference call. “You should have already been started up and ramped up, and get ready to revenue up. We think we are.”
However, it doesn’t make sense nor is it fair to put all the blame to cannabis. There are also other factors at play such as a predisposition to use harder drugs, existing problem behavior, emotional problems, and peer pressure, all of which can contribute to undesirable life outcomes such as higher risk for dropping out of school, welfare dependence, and unemployment.
In modern times, the Rastafari movement has embraced Cannabis as a sacrament. Elders of the Ethiopian Zion Coptic Church, a religious movement founded in the United States in 1975 with no ties to either Ethiopia or the Coptic Church, consider Cannabis to be the Eucharist, claiming it as an oral tradition from Ethiopia dating back to the time of Christ. Like the Rastafari, some modern Gnostic Christian sects have asserted that Cannabis is the Tree of Life. Other organized religions founded in the 20th century that treat Cannabis as a sacrament are the THC Ministry, Cantheism, the Cannabis Assembly and the Church of Cognizance. Rastafarians tend to be among the biggest consumers of modern Cannabis use.
I’m ordinarily not a chocolate or sweets person. But when it comes to edibles, this delivery method works best for me when I’m traveling and away from my kitchen. Kiva’s products are what I carry whenever work (or pleasure) takes me on extended trips. The ginger dark chocolate and espresso dark chocolate are my favorites. They’ve got just enough THC and CBD to help ward off jet lag and fatigue. I also take them when I’m extra sore from running or Krav Maga. (It really does wonders for pain and inflammation.) But it’d be a disservice if I only mentioned Kiva’s chocolates. The company also offers Camino gummies, of which the sparkling pear and wild berry, are superb. The THC-only Terra Bites chocolate-covered blueberries are a gift from the gods—they work, they fit nicely in my purse, and they’re delicious. Also: a single dose (5mg) is low enough so that when paired with a CBD-only confection, such as Lord Jones’ gumdrops, there’s not really a high. You only get a pleasant mellowness that radiates throughout your body, which is almost akin to a mild boozy buzz—in a happy and good way. (In budtender lingo, it’s called a body high.)
Nabiximols (brand name Sativex) is a patented medicine containing CBD and THC in equal proportions. The drug was approved by Health Canada in 2005 for prescription to treat central neuropathic pain in multiple sclerosis, and in 2007 for cancer related pain. In New Zealand Sativex® is approved for use as an add-on treatment for symptom improvement in patients with moderate to severe spasticity due to Multiple Sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
^ Jump up to: a b This paper begins with a history of hemp use and then describes how hemp was constructed as a dangerous crop in the U.S. The paper then discusses the potential of hemp as an alternative crop. Luginbuhl, April M. (2001). "Industrial hemp (Cannabis sativa L): The geography of a controversial plant". The California Geographer (PDF). 41. California Geographical Society. pp. 1–14. Retrieved 2013-03-28. Hemp contains less than 1% THC, or tetrahydrocannabinols, the psychoactive property in marijuana. In other words, smoking hemp cannot create a 'high.' ... The dense growth of hemp eliminates other weeds.... The best growing technique for hemp, planting 300 to 500 plants per square meter, also helps authorities easily tell the hemp from marijuana, which is a plant that is less densely cultivated. (Roulac 1997; 149).
Cultivated industrial hemp plants usually consist of a spindly main stalk covered with leaves. Considered a low-maintenance crop, hemp plants typically reach between 6 to 15 feet in height. Depending on the purpose, variety and climatic conditions, the period between planting and harvesting ranges from 70 to 140 days. One acre of hemp can yield an average of 700 pounds of grain, which in turn can be pressed into about 22 gallons of oil and 530 pounds of meal. The same acre will also produce an average of 5,300 pounds of straw, which can be transformed into approximately 1,300 pounds of fiber.
The genus Cannabis was first classified using the "modern" system of taxonomic nomenclature by Carl Linnaeus in 1753, who devised the system still in use for the naming of species. He considered the genus to be monotypic, having just a single species that he named Cannabis sativa L. (L. stands for Linnaeus, and indicates the authority who first named the species). Linnaeus was familiar with European hemp, which was widely cultivated at the time. In 1785, noted evolutionary biologist Jean-Baptiste de Lamarck published a description of a second species of Cannabis, which he named Cannabis indica Lam. Lamarck based his description of the newly named species on plant specimens collected in India. He described C. indica as having poorer fiber quality than C. sativa, but greater utility as an inebriant. Additional Cannabis species were proposed in the 19th century, including strains from China and Vietnam (Indo-China) assigned the names Cannabis chinensis Delile, and Cannabis gigantea Delile ex Vilmorin. However, many taxonomists found these putative species difficult to distinguish. In the early 20th century, the single-species concept was still widely accepted, except in the Soviet Union where Cannabis continued to be the subject of active taxonomic study. The name Cannabis indica was listed in various Pharmacopoeias, and was widely used to designate Cannabis suitable for the manufacture of medicinal preparations.
The reason so many people are interested in cannabis products that don’t make them high, proponents say, is that CBD helps with everything from pain and nausea to rheumatoid arthritis, cancer, Crohn’s disease, and dementia. CBD is anti-inflammatory, anti-anxiety, antibacterial, immunosuppressive, and more, says Joseph Cohen, D.O., a cannabis doctor in Boulder, CO.
In the mid 1990s, the EU provided subsidization for hemp cultivation of ca. $1,050/ha. This support was instrumental in developing a hemp industry in western Europe. However, no comparable support is available in North America, and indeed those contemplating entering into hemp cultivation are faced with extraordinary costs and/or requirements in connection with licensing, security, THC analysis, and record keeping. Those involved in value-added processing and distribution are also faced with legal uncertainties and the regular threat of idiosyncratic, indeed irrational actions of various governments. Simply displaying a C. sativa leaf on advertising has led to the threat of criminal charges in the last decade in several G8 countries. Attempting to export or import hemp products among countries is presently a most uncertain activity.
Buying online is less reliable still because there’s no regulation or standardization. What you see on the label may not be what you are getting. A 2017 study in JAMA found that of the 84 CBD products researchers bought online, 43% had more CBD than indicated, while 26% had less, and some had unexpected THC. “There’s a 75% chance of getting a product where the CBD is mislabeled,” says Marcu, one of the study’s coauthors.
3. Is the CBD oil sold by Hempworx a bad product? No. To their credit, Hempworx does post third party lab reports posted on its website. Third party lab reports are the only way to really know what’s in the product you are buying. The Hempworx lab reports clearly show the amount of CBD and other cannabinoids including trace amounts of THC in the Hempworx CBD oil tincture. By all accounts, Hempworx CBD oil is of reasonably good quality. However, it’s worth noting that their posted lab reports do not show results of heavy metal, pesticide and residual solvents testing. The omission of these test results is concerning.
Focusing more on lifestyle issues and their relationships with functional health, data from the Alameda County Study suggested that people can improve their health via exercise, enough sleep, maintaining a healthy body weight, limiting alcohol use, and avoiding smoking. Health and illness can co-exist, as even people with multiple chronic diseases or terminal illnesses can consider themselves healthy.
That leaves those touting CBD’s effectiveness pointing primarily to research in mice and petri dishes. There, CBD (sometimes combined with small amounts of THC) has shown promise for helping pain, neurological conditions like anxiety and PTSD, and the immune system—and therefore potentially arthritis, diabetes, multiple sclerosis, cancer, and more.
The results of the three large European cohort studies have been confirmed in two smaller New Zealand birth cohorts. Arsenault and colleagues (2002) reported a prospective study of the relationship between adolescent cannabis use and psychosis in a New Zealand birth cohort (n = 759). They found a relationship between cannabis use by age 15 and an increased risk of psychotic symptoms by age 26. The relationship did not change when they controlled for other drug use, but it was no longer statistically significant after adjusting for psychotic symptoms at age 11. The latter probably reflected the small number of psychotic disorders observed in the sample. Fergusson et al. (2003) found a relationship between cannabis dependence at age 18 and later symptoms that included those in the psychotic spectrum reported at age 21 in the Christchurch birth cohort. Fergusson and colleagues adjusted for a large number of potential confounding variables, including self-reported psychotic symptoms at the previous assessment, other drug use and other psychiatric disorders, but whether the association represents a link between cannabis use and psychotic symptoms specifically, or more general psychiatric morbidity, remains unclear.